Published in AIDS Weekly, March 9th, 1998
Results from a Phase II clinical trial point to a positive answer.
The trial investigated the ability of Pasteur Merieux/Connaught's new canarypox-based HIV vaccine - given alone or in various combinations with Chiron's rgp120 SF2 HIV peptide vaccine - to evoke HIV specific CD8+ CTL responses.
"A strategy of inclusion of multiple [HIV] genes into a canarypox vector given with rgp120 SF2 results in neutralizing antibodies and broad and durable CD8+ CTL," reported T.G. Evans of the University of Rochester,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.